Amneal Pharmaceuticals Reports Third Quarter 2026 Financial Results and Raises Full-Year Guidance

Amneal Pharmaceuticals reported third-quarter 2026 net revenue of $863 million, up 10% year over year, and adjusted EBITDA of $207 million, up 30%. Adjusted diluted EPS rose 53% to $0.26, with growth in Specialty and Affordable Medicines supported by new biosimilar and injectable launches. The company raised its full-year 2026 guidance for revenue, adjusted EBITDA, and adjusted diluted EPS, and said integration of its Kashiv acquisition is proceeding as planned.